Related Experiment Video
Updated: Jun 24, 2026
10:21
Protein Target Prediction and Validation of Small Molecule Compound
Published on: February 23, 2024
[Therapeutic targets].
1Unité de Neurogastroenterologie et Nutrition, 180 Chemin de Tournefeuille-BP3, 31931 Toulouse, France. lbueno@toulouse.inra.fr
Gastroenterologie Clinique Et Biologique
|March 24, 2009
Summary
The treatment of irritable bowel syndrome (IBS) is shifting from motility drugs to visceral antinociceptive medications. New therapies target gut hyperalgesia and mucosal inflammation by addressing altered barrier permeability.
Area of Science:
- Gastroenterology and Pharmacology
- Visceral pain mechanisms and therapeutic targets
Context:
- Irritable bowel syndrome (IBS) treatment paradigms are evolving based on new insights into visceral hyperalgesia.
- Traditional therapies focused on motility disorders are being superseded by approaches targeting pain pathways.
Purpose:
- To review the changing therapeutic strategies for IBS, emphasizing the shift towards visceral antinociceptive drugs.
- To highlight the role of mucosal immune stimulation and altered barrier permeability in IBS pathophysiology.
- To identify novel drug targets for IBS treatment based on emerging pathophysiological understanding.
Summary:
- Recent research identifies key mediators (e.g., serotonin, tachykinins) and receptors involved in gut hyperalgesia.
- IBS is linked to mucosal immune activation and increased intestinal permeability, driven by luminal factors.
- Development of drugs targeting these mechanisms, particularly those preventing barrier alterations, shows promise for IBS.
Impact:
- This shift offers a more pathophysiologically targeted approach to IBS management.
- Future IBS therapies may focus on preventing microinflammation and restoring mucosal barrier integrity.
- Novel drug development holds potential for effective, disease-modifying treatments for IBS patients.
Related Concept Videos
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...